• 5 min read
• Published on 16 November 2025
Listen to article
6:32Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article
Let’s be honest, there’s a quiet panic brewing in the boardrooms of the world’s largest pharmaceutical companies. You can almost picture the scene. An executive stares at a calendar, watching the days tick down to the moment their blockbuster drug, the one that’s been funding the company car park and the lavish Christmas parties for a decade, goes off-patent. When that happens, generic competition floods in, and revenues fall off a cliff. It’s a terrifying prospect.
This so-called ‘patent cliff’ is forcing these giants to go shopping. They are desperately hunting for the next big thing, and right now, their eyes are firmly fixed on the innovative, nimble world of antiviral biotechnology.
When a company like Merck splashes out a cool $9.2 billion on a firm like Cidara Therapeutics, it’s not just a casual purchase. It’s a statement of intent. They aren’t just buying a single drug, they are buying a foothold in a future where fighting infectious diseases is paramount. To me, this signals the start of a much larger trend. Big Pharma has deep pockets and an urgent problem, a combination that almost always leads to a flurry of mergers and acquisitions.
The COVID-19 pandemic served as a brutal, global wake-up call. It reminded everyone that we are perpetually one novel virus away from chaos. Consequently, governments and healthcare systems are now willing to pay a premium for preparedness, and pharmaceutical companies have realised that having a strong antiviral pipeline is no longer a niche specialism, it’s a strategic necessity. This is the core idea behind the Antiviral M&A Wave: Biotech Opportunities in 2025 investment theme.
So, who are the potential targets in this high-stakes game? Well, you have companies that have spent years quietly building expertise in this very specific field. Take a firm like Vir Biotechnology. They’ve been focusing on tricky chronic infections like hepatitis B. Then there’s Invivyd, which is all about developing antibody therapies to tackle whatever nasty virus is currently doing the rounds. And you have Atea Pharmaceuticals, which is working on the holy grail of treatment, simple oral pills to fight serious viral infections.
I’m not saying any of these are guaranteed to be snapped up, of course. But they represent the exact profile of company that a lumbering pharmaceutical giant might covet. They are agile, innovative, and possess assets that could take years and billions for a larger company to develop from scratch. It’s often far easier, and ultimately cheaper, to simply buy the solution.
Now, before you get too carried away, a dose of realism is required. Investing in clinical-stage biotech is not for the faint of heart. It’s a sector built on hope and hypotheses, and it can be incredibly volatile. A promising drug can fail in a late-stage trial, and when that happens, a company’s share price can evaporate overnight. There are no sure things here.
The timing is also completely unpredictable. An acquisition could be announced next week, or it could be years away, or it might never happen at all. You need patience and a stomach for risk. However, the potential upside is what makes it so compelling. When a deal is announced, it’s not uncommon to see acquisition premiums of 50 to 100 percent. For investors who understand the risks, the potential rewards for backing the right horse can be substantial.
View the full Basket:Antiviral M&A Wave: Biotech Opportunities in 2025
View the full Basket:Antiviral M&A Wave: Biotech Opportunities in 2025
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article